In IVF, every egg counts. And for women with PCOS or metabolic irregularities, improving the quality of those eggs can make the difference between disappointment and a viable embryo. That’s why the March 2025 systematic review and meta-analysis published in Frontiers in Endocrinology deserves our attention.
This paper pooled data from 11 clinical studies across 981 women undergoing IVF or ICSI, comparing those who took myo-inositol (MI) supplements versus those who didn’t. The results are compelling—especially for women with PCOS, where the path to fertility is often blurred by insulin resistance, irregular cycles, and compromised egg development.
AT A GLANCE
A new meta-analysis shows how myo-inositol impacts IVF success. In this article we’ll take you through what the data shows, and what it means in practical terms. Key findings:
- Inositol improved egg quality (not quantity)
- Doubles egg maturity odds in PCOS
- Fertilization rates were notably higher with inositol
WHO WAS STUDIED?
Before diving into the results, here’s the landscape: where the research was done, who it involved, and how the inositol was taken.
- Total participants: 981 women (478 received MI + folic acid; 503 received folic acid or placebo only)
- Geographies: Studies conducted in Iran, Italy, Germany, Japan—mostly in PCOS and IVF centers
-
Participants grouped as:
- PCOS (Polycystic Ovary Syndrome)
- Non-obese PCOS (subset of above)
- POR (Poor Ovarian Responders)
-
General IVF population (no PCOS or POR diagnosis)
All studies used 4g/day of MI, often combined with 400 mcg folic acid, taken 1–3 months before IVF stimulation and through ovulation triggering.
HOW WELL DID EGGS MATURE?
(MII OOCYTE RATE)
This metric tells us how many eggs were fully mature—meaning they were actually capable of being fertilized.
-
Across all women, MI increased the odds of retrieving mature eggs by 55%
(Odds Ratio [OR] 1.55, p=0.03) -
PCOS group: Odds of having mature eggs improved by 97%
(OR 1.97, p<0.01) -
Non-obese PCOS: Very similar benefit—92% increase
(OR 1.92, p=0.02) -
POR group: No statistically meaningful improvement
(OR 0.97, p=0.95)
What this means: If you have PCOS, MI could nearly double your chances of retrieving fertilization-ready eggs. But if you’re a poor responder due to age or diminished ovarian reserve, MI may not make a difference in egg maturity—highlighting that it works best by correcting metabolic, not age-related, dysfunction.
DID THE EGGS FERTILIZE?
(FERTILIZATION RATE)
This part looks at what happened after the eggs were retrieved—did they actually fertilize and start to grow?
-
Overall improvement: Fertilization odds were 62% higher in the MI group
(OR 1.62, p<0.01) -
PCOS group: Fertilization odds up 59%
(OR 1.59, p<0.01) -
Non-obese PCOS: Even higher, with an 87% increase
(OR 1.87, p<0.01) -
POR women: Fertilization success improved by 142%
(OR 2.42, p<0.01)
What this means: Even when MI didn’t improve egg maturity (as with POR), it still helped with fertilization. That suggests MI may enhance the egg’s internal environment or support better sperm-egg interaction—likely through improved insulin signaling and cellular energy metabolism.
DID WOMEN PRODUCE MORE EGGS OR BETTER EMBRYOS?
This section looks at total egg count and embryo quality—not just maturity or fertilization.
-
No significant difference in total oocytes across all groups
(Mean Difference 0.22, p=0.50) -
High-quality embryo rate: Not significantly better in MI users
(OR 1.54, p=0.46)
Takeaway: MI isn’t increasing egg quantity, but it is improving functional quality—which matters more for fertilization and embryo viability.
DID MORE WOMEN ACTUALLY GET PREGNANT? (CLINICAL PREGNANCY RATE)
This outcome measures how many women achieved pregnancy confirmed by ultrasound after embryo transfer.
-
While there was a trend toward higher pregnancy rates in the MI group, the difference was not statistically significant
(OR 1.53, p=0.09)
What this means: MI may improve the chances of a viable embryo, but pregnancy outcomes still depend on many other factors: uterine environment, immune function, embryo genetics. MI helps—but it’s not the whole story.
WHY IS THIS WORKING?
Let’s connect the dots—why would MI improve egg quality and fertilization?
Myo-inositol enhances:
- Insulin sensitivity (crucial for PCOS-related metabolic dysfunction)
- FSH receptor activity (essential for egg development)
- Intracellular calcium signaling (supports egg maturation and fertilization)
- Oxidative stress reduction (protects egg quality)
In PCOS, where insulin resistance disrupts hormonal rhythms and ovarian function, MI helps reset the system—without the side effects of pharmaceuticals like metformin.
THE TAKEAWAY: RIGHT TOOL, RIGHT BIOLOGY
This meta-analysis confirms what many functional practitioners have long suspected: Myo-inositol works best when insulin resistance or metabolic dysfunction is the root cause. For PCOS patients—especially those not overweight—this is a validated, non-invasive, affordable intervention that can meaningfully improve IVF outcomes.
It’s not a fertility hack. It’s metabolic support. And when the metabolic system is supported, better eggs—and better outcomes—follow.
— Bodology Editorial Team
